中文

冠昊生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥0.09B-1.4%
Gross profit¥0.07B
Operating income¥0.01B
Net income¥0.01B-51.1%
Gross margin76.6%Net margin 7.7%
Revenue Q/Q-0.9%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.02B23.4%
R&D¥0.01B8.6%
SG&A¥0.05B55.1%
Tax & other¥0.00B3.7%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

东宝生物飞力达瑞丰光电佳云科技瑞丰高材迪安诊断ST天玑宝莱特融捷健康新开普依米康初灵信息

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies